Interferon therapy for hepatitis C.
Initial trials indicated that around 50% of patients respond to recombinant alpha interferon by normalizing alanine aminotransferase (ALT) at the end of therapy and that half of these relapsed within 6 months following cessation of treatment. Both dose and duration of treatment are critical in the response to therapy. Higher doses and longer duration have been suggested to be more effective than the current recommendations of 3 MUI thrice weekly for 6 months based on results of these initial studies which used ALT and histological scores to evaluate the efficacy of interferon therapy. Following studies using virological markers have shown that improvements in clinical features of disease are associated with decrease or loss of hepatitis C virus (HCV) from serum and liver. The heterogeneity of the response rates between clinical centers using identical protocol emphasizes that the selection of the patients treated was as important for the outcome that the therapy regimen itself with better responses in cases without cirrhosis and with low levels of HCV RNA. Furthermore, the genotype of HCV seems to be also critical for the response rate. Virological evaluations appears therefore crucial to assess not only HCV infection but also for the indication and monitoring of therapy.
Service d'Hépato-gastroentérologie, Hopital Hotel-Dieu, Lyon, France.
C
C
Trépo
F
F
Habersetzer
F
F
Bailly
F
F
Berby
C
C
Pichoud
P
P
Berthillon
L
L
Vitvitski
D000410:Alanine Transaminase / Q000097:blood; D002986:Clinical Trials as Topic / Q000592:standards*; D004305:Dose-Response Relationship, Drug; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D018579:Patient Selection; D012254:Ribavirin / Q000627:therapeutic use
D016898:Interferon-alpha; D012254:Ribavirin; D000410:Alanine Transaminase